WESTMINSTER, Colo., Nov. 8 /PRNewswire-FirstCall/ -- Allos Therapeutics,
Inc. (Nasdaq: ALTH) today announced that data evaluating the Company's product
candidates EFAPROXYN (efaproxiral) and RH1 have been accepted for presentation
at the following scientific conferences:
* AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics: Sarah Danson, M.D., Department of Medical
Oncology, Christie Hospital, is scheduled to report updated clinical
and PK/PD data from an on-going Phase 1 study of RH1 in patients with
advanced solid tumors in a poster presentation titled "Phase 1
Pharmacokinetic (PD) trial of the bioreductive drug RH1" on Thursday,
November 17.
* San Antonio Breast Cancer Symposium: Charles Scott, Ph.D., CBS
Squared, is scheduled to present a quality adjusted survival analysis
of the Phase 3 REACH study of EFAPROXYN in patients with brain
metastases in a poster presentation titled "Improved survival, quality
of life and quality-adjusted survival in breast cancer patients
treated with efaproxiral + whole brain radiation therapy for brain
metastases" on Saturday, December 10.
Copies of the abstracts will be available on the AACR (http://www.AACR.org) and
SABCS (http://www.SABCS.org) web sites.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company
focused on developing and commercializing innovative small molecule
therapeutics for the treatment of cancer. The Company's lead product
candidate, EFAPROXYN(TM) (efaproxiral), is a synthetic small molecule designed
to sensitize hypoxic, or oxygen-deprived, tumor tissue during radiation
therapy. EFAPROXYN is currently being evaluated as an adjunct to whole brain
radiation therapy in a pivotal Phase 3 trial in women with brain metastases
originating from breast cancer. The Company's other product candidates are:
PDX (pralatrexate), a small molecule chemotherapeutic agent (DHFR inhibitor)
currently under investigation as both a single agent and in combination
therapy regimens in patients with non-small cell lung cancer and Non-Hodgkin's
lymphoma; and RH1, a small molecule chemotherapeutic agent bioactivated by the
enzyme DT-diaphorase currently under evaluation in patients with advanced
solid tumors. For more information, please visit the Company's web site at:
http://www.allos.com.
Safe Harbor Statement
The anticipated presentations will contain forward-looking statements that
involve significant risks and uncertainties, including those to be discussed
in the presentation and others that can be found in the "Risk Factors" section
of the Company's Form 10-K for the year ended December 31, 2004 and in the
Company's periodic reports on Form 10-Q and Form 8-K. The Company does not
undertake any obligation to update any forward-looking statements contained in
the anticipated presentation as a result of new information, future events or
otherwise. The Company cautions investors not to place undue reliance on the
forward-looking statements contained in the presentation. No forward-looking
statement can be guaranteed and actual events and results may differ
materially from those projected.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com
CONTACT:
Jennifer Neiman, Manager, Corporate
Communications of Allos Therapeutics, +1-720-540-5227,
jneiman@allos.com
|
